Somatostatin Analogue

PET-CT

Food and drug administration

Somatostatin receptor

Octreotide

Neuroendocrine tumors

Chelation

Somatostatin

Medical physics

DOTA

Radiology

Organic chemistry

Radionuclide therapy

Pet imaging

Internal medicine

Pharmacology

Medicine

Chemistry

Nuclear medicine

Positron emission tomography

Pharmaceuticals

In the United States, [68Ga]Ga-DOTA-TOC has been approved by the Food and Drug Administration (FDA) in 2019 as the first 68Ga-radiopharmaceutical for imaging of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors while employing positron emission tomography (PET). In Europe (Austria, Germany, France), [68Ga]Ga-DOTA-TOC was already approved back in 2016. This radiopharmaceutical combines the radionuclide 68Ga with the somatostatin analogue DOTA-TOC for specific imaging of tumor cells expressing SSTRs. Such a targeting approach can also be used for therapy planning in the case of both localized as well as disseminated disease and potentially for the evaluation of treatment response.

[68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging